Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Condition:   Diabetes Mellitus, Type 2 Interventions:   Drug: ITCA 650 20/60 mcg/day;   Drug: Empagliflozin (oral);   Drug: Glimepiride (oral) Sponsor:   Intarcia Therapeutics Not yet recruiting - verified February 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials